{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":46,"searchCount":0},"additional":{"submitter":["Gavor E"],"funding":["Ministry of Education - Singapore"],"pagination":["1006-1022"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7498231"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(11)"],"pubmed_abstract":["The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, and discuss current progress in antibody research against rampant SARS-CoV-2 infections. We provide a perspective on the mechanisms of SARS-CoV-2-derived nAbs, comparing these with existing SARS-CoV-derived antibodies. We offer insight into how these antibodies cross-react and cross-neutralize by analyzing available structures of spike (S) glycoprotein-antibody complexes. We also propose ways of adopting antibody-based strategies - such as cocktail antibody therapeutics against SARS-CoV-2 - to overcome the possible resistance of currently identified mutants and mitigate possible antibody-dependent enhancement (ADE) pathologies. This review provides a platform for the progression of antibody and vaccine design against SARS-CoV-2, and possibly against future coronavirus pandemics."],"journal":["Trends in immunology"],"pubmed_title":["Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions."],"pmcid":["PMC7498231"],"funding_grant_id":["R-154-000-B03-112","R-154-000-697-112","R154-000-A72114"],"pubmed_authors":["Gavor E","Sivaraman J","Er SY","Choong YK","Sivaraman H"],"view_count":["46"],"additional_accession":[]},"is_claimable":false,"name":"Structural Basis of SARS-CoV-2 and SARS-CoV Antibody Interactions.","description":"The 2019 coronavirus pandemic remains a major public health concern. Neutralizing antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV, and discuss current progress in antibody research against rampant SARS-CoV-2 infections. We provide a perspective on the mechanisms of SARS-CoV-2-derived nAbs, comparing these with existing SARS-CoV-derived antibodies. We offer insight into how these antibodies cross-react and cross-neutralize by analyzing available structures of spike (S) glycoprotein-antibody complexes. We also propose ways of adopting antibody-based strategies - such as cocktail antibody therapeutics against SARS-CoV-2 - to overcome the possible resistance of currently identified mutants and mitigate possible antibody-dependent enhancement (ADE) pathologies. This review provides a platform for the progression of antibody and vaccine design against SARS-CoV-2, and possibly against future coronavirus pandemics.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2024-11-20T01:06:19.793Z","creation":"2020-10-29T09:31:25Z"},"accession":"S-EPMC7498231","cross_references":{"pubmed":["33041212"],"doi":["10.1016/j.it.2020.09.004"]}}